IMUNON to Present at Chardan’s 6th Annual Genetic Medicines Conference
LAWRENCEVILLE, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) — Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development…
Year: 2022
IMUNON to Present at Chardan’s 6th Annual Genetic Medicines Conference
LAWRENCEVILLE, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) — Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development…
IMUNON to Present at Chardan’s 6th Annual Genetic Medicines Conference
LAWRENCEVILLE, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) — Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development…
Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…
Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…
Wave Life Sciences to Present at Chardan’s 6th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…
Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
New study size of 140 patients for the REBUILD Study, without modifying trial objective or…
Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
New study size of 140 patients for the REBUILD Study, without modifying trial objective or…
Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
New study size of 140 patients for the REBUILD Study, without modifying trial objective or…
BrightInsight Adds Xealth, Woebot Health and Claritas Rx to the BrightInsight Ecosystem
Companies Will Collaborate to Drive Digital Innovation, Adoption and Engagement SAN JOSE, Calif., Sept. 27,…
BrightInsight Adds Xealth, Woebot Health and Claritas Rx to the BrightInsight Ecosystem
Companies Will Collaborate to Drive Digital Innovation, Adoption and Engagement SAN JOSE, Calif., Sept. 27,…
BrightInsight Adds Xealth, Woebot Health and Claritas Rx to the BrightInsight Ecosystem
Companies Will Collaborate to Drive Digital Innovation, Adoption and Engagement SAN JOSE, Calif., Sept. 27,…
Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD
ISELIN, N.J. and CONSHOHOCKEN, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq:…
Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD
ISELIN, N.J. and CONSHOHOCKEN, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq:…
Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD
ISELIN, N.J. and CONSHOHOCKEN, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq:…
Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress
Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds…
Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress
Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds…
Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress
Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds…
Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors
REHOVOT, Israel and WILMINGTON, Del., Sept. 27, 2022 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq:…
Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors
REHOVOT, Israel and WILMINGTON, Del., Sept. 27, 2022 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (Nasdaq:…